Wade J C, Hintz M, McGuffin R, Springmeyer S C, Connor J D, Meyers J D
Am J Med. 1982 Jul 20;73(1A):249-56. doi: 10.1016/0002-9343(82)90100-0.
Cytomegalovirus pneumonia is a serious complication of marrow transplantation, with a 90 percent fatality rate. Acyclovir, a new antiviral agent with variable in vitro activity against cytomegalovirus, was administered to eight marrow transplant patients with biopsy-proven cytomegalovirus pneumonia; one patient survived. Doses were between 400 and 1200 mg/m2 and peak plasma levels between 47 and 316 microM were attained. Possible marrow toxicity occurred in three patients, and mild neurotoxicity occurred in one. High-dose acyclovir had mild toxicity but was not effective as treatment for cytomegalovirus pneumonia after marrow transplantation.
巨细胞病毒肺炎是骨髓移植的一种严重并发症，死亡率达90%。阿昔洛韦是一种对巨细胞病毒具有不同体外活性的新型抗病毒药物，对8例经活检证实患有巨细胞病毒肺炎的骨髓移植患者使用了该药物；1例患者存活。剂量在400至1200mg/m²之间，血浆峰值水平达到47至316微摩尔。3例患者出现可能的骨髓毒性，1例出现轻度神经毒性。高剂量阿昔洛韦毒性轻微，但对骨髓移植后巨细胞病毒肺炎无效。
